STOCK TITAN

Design Therapeutics, Inc. - DSGN STOCK NEWS

Welcome to our dedicated news page for Design Therapeutics (Ticker: DSGN), a resource for investors and traders seeking the latest updates and insights on Design Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Design Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Design Therapeutics 's position in the market.

Rhea-AI Summary
Design Therapeutics, Inc. (DSGN) announces the development of new drug products for Friedreich Ataxia, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease. The company plans to start patient trials in 2025, with a strong financial position supporting its operations for the next five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.97%
Tags
-
Rhea-AI Summary
Design Therapeutics, Inc. (DSGN) to host a conference call and webcast to discuss Q4 and full year 2023 financial results and portfolio update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences earnings
-
Rhea-AI Summary
Design Therapeutics, Inc. (Nasdaq: DSGN) reported Q3 2023 financial results, announcing the appointment of Pratik Shah as CEO. The company initiated a strategic realignment to prioritize long-term growth, focusing on GeneTAC™ small molecules to treat genetic diseases. With a cash position of ~$290M, Design expects to fund operating expenses for at least the next five years. Dr. Shah highlighted the potential of GeneTAC™ molecules in treating diseases like Friedreich ataxia, Fuchs endothelial corneal dystrophy, and myotonic dystrophy type-1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.71%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.66%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.79%
Tags
conferences
Design Therapeutics, Inc.

Nasdaq:DSGN

DSGN Rankings

DSGN Stock Data

210.16M
24.14M
36.67%
56.79%
3.95%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CARLSBAD